MT-CYB and infection: Of the 13 compounds we tested in tarsal-contact assays, only our most potent hit in the topical screen, ELQ-456 (CytB Qo-site inhibitor) reduced infection (69.5% reduction in oocyst prevalence) (Fig. 2b,c).